

**Other Support****Garnet Anderson****Active**

<b>N01 WH-2-2110 (Prentice and Anderson)</b>	09/30/92 – 03/31/11	4.8 cal mos
NIH	\$10,388,400	40%

Women's Health Initiative Coordinating Center (Extension)

The Fred Hutchinson Cancer Research Center operates the Clinical Coordinating Center for the Women's Health Initiative Clinical Trial and Observational Study. The clinical trial (sample size 64,500) is evaluating the impact of a low fat diet eating pattern, of hormone replacement, and of calcium and vitamin D supplementation for the primary prevention of breast and colorectal cancer, coronary heart disease, and bone fractures. The Observational Study (sample size 100,000) is studying various risk factors for the same range of disease. The CT and OS are conducted in postmenopausal women in the age range 50-79.

<b>5 U10 CA38926 (Crowley)</b>	01/01/10– 12/31/15	1.8 cal mos
NIH/National Cancer Institute	\$3,983,675	15%

Southwest Oncology Group Statistical Center

The Southwest Oncology Group is a national consortium of institutions and investigators organized to improve survival of cancer patients through clinical research. The Statistical Center staff at Fred Hutchinson Cancer Research Center (FHCR) assist with study protocols, manage and edit study data, generate semiannual reports of findings, and conduct workshops on data management activities. They also research statistical aspects of Group studies and analyze and publish study results. Several programs previously funded via the Group Operations Office/Cancer Therapy and Research Center are included here: Cooperative Group Outreach Program (CGOP), Pathology Central Office, Urologic Cancer Outreach Program (UCOP), CTEP Minorities Program, High Priority Clinical Trials and Leukemia Biology.

<b>1 U01 HG0047901-01 (Kooperberg)</b>	7/17/08 – 5/31/12	.6 cal mos
NHGRI/NCI	\$1,093,576 (year 1 direct costs)	5%

Epidemiology of Putative Genuine Genetic Variants: The Women's Health Initiative

The goal of this application is to examine the population incidence for racial and ethnic subgroups and associated risks of rigorously define, incident diseases; to investigate associated risks given in-depth information on various environmental exposures and disease risk factors as well as three randomized interventions; and to link genetic variants to relevant intermediate phenotypes.

<b>1 U01 AG032699-01 (LaCroix and Anderson)</b>	09/15/08 - 06/30/13	1.8 cal mos
NIH/NIA	\$2,028,335 (annual direct Yr 1)	15%

Menopause Strategies - Finding Lasting Answers for Symptoms and Health (Ms-FLASH)

The long-term objective is to accelerate progress in identifying effective remedies for vasomotor symptoms (VMS) in women going through the menopausal transition. The Data Coordinating Center (DCC) will provide and coordinate all necessary leadership activities to facilitate collaboration and productivity in this group during all phases in the lifecycle of VMS clinical trials from hypothesis formulation to publication, dissemination, and data sharing. In conjunction with the network entitled, "The Menopausal Symptoms Initiative-Finding Lasting Answers to Sweats and Hot Flashes (MSI-FLASH)", five randomized controlled trials testing a range of behavioral, mind-body, hormonal and pharmacologic interventions to treat hot flashes are proposed (yoga and ultra low-dose E2 gel). To study these effects a factorial design RCT is planned which will also allow evaluation of the additive effect of these interventions, that is, whether the two combined are superior to either alone. *The primary aims of this randomized controlled trial are to:* 1) evaluate the effects of yoga vs. no yoga on: a) subjective VMS frequency ; and b) VMS bothersomeness; and 2) evaluate the effects of ultra-low dose E2 gel vs. placebo gel on: a) subjective VMS frequency; and b) VMS bothersomeness.

It is also proposed to recruit participants for three other randomized trials for this network application; an SSRI trial, a slow deep breathing trial, and an exercise intervention trial.

<b>University of Michigan (Baker)</b>	10/01/08 – 07/31/11	1.20 cal mos
<b>Gates Foundation</b>	\$986,962 (CRAB direct costs)	10%

A Clinical Trial of *Helicobacter pylori* Eradication in Latin America

Our long-term goal is to prevent gastric cancer by developing and validating an effective, simple, and low-cost approach to eradication of *H. pylori*. The immediate goal is to develop and implement a randomized clinical trial of gastric cancer prevention based on eradication of *H. pylori* infection among adults in Mexico and Central and South America. The plan involves two phases: 1) the initial phase of two years in which we will conduct a randomized study among 1,400 participants to determine the preferred antibiotic intervention, and 2) the definitive phase of 10 years for the randomized trial in 50,000–100,000 adults.

<b>BAA-NHLBI-WH-09-01 (McIntosh)</b>	01/15/09 – 01/14/11	0.24 cal mos
NIH		2%

Discovery and Confirmation of Cancer Specific Serum Protein Markers for Ovarian Cancer Early Detection  
The primary goal of this study is to use state of the art proteomics technologies and novel computational strategies to identify serum proteins that can detect the majority of women with serous ovarian cancer three years before diagnosis.

<b>U10 CA37429 (Baker)</b>	06/01/01 - 05/31/11	0.6 cal mos
NIH/NCI/CTRC	\$419,815	5%

CCOP Community Clinical Oncology Program

CRAB provides behavioral science and statistical expertise, as well as data management support for cancer control activities related to cancer clinical trials.

<b>NIH 1U01HG005152 (Reiner)</b>	09/30/09 – 8/31/2012	.24 cal mo Yr1; .36 cal mo Yr2; .6 cal mo Yr3
NHGRI	\$1,563,732	(2% Yr1; 3% Yr2; 5% Yr3)

GWAS of Hormone Treatment and CVD and Metabolic Outcomes in the WHI

The goal of this project is to carry out a genome-wide association study in a randomized clinical trial of post-menopausal women to identify genetic variants that can be associated with a response to hormone therapy.

<b><u>Institutional Support</u></b>	Ongoing- as needed	1.2 cal mos
Fred Hutchinson Cancer Research Center		10.0%

### **Overlap**

Currently, there is no scientific or budgetary overlap. At no time will her effort exceed 100%, or 12 calendar months.